Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00935792 · ClinicalTrials.gov registry record · Phase 1
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 1 study of Lymphocytic Leukemia, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT00935792: Completed Phase 1 study of Lymphocytic Leukemia, sponsored by Mayo Clinic.
NCT00935792 is a Phase 1 study of Lymphocytic Leukemia that has completed, run by Mayo Clinic. The registered enrollment target is 28 participants, above the 22-participant average among 4 other Lymphocytic Leukemia trials with a reported enrollment target (27% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00935792, a Phase 1 study of Lymphocytic Leukemia, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the signaling molecules needed for cell growth. Monoclonal antibodies, such as alemtuzumab, can bind to and kill malignant lymphocytes. PURPOSE: This phase I/II trial is studying the side effects and best dose of everolimus when given together with alemtuzumab and will see how well they work in treating patients with recurrent chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL).
Conditions Studied
Interventions
- DRUG everolimus
- DRUG alemtuzumab
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-07 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00935792
The ClinicalTrials.gov registry entry for NCT00935792 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 22-participant average among 4 other Lymphocytic Leukemia trials with a reported enrollment target (27% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which everolimus is the first listed.
NCT00935792 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00935792 about?
NCT00935792 is a clinical study titled "Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the signaling molecules needed for cell growth. Monoclonal antibodies, such as alemtuzumab, can bind to and kill malignant lymphocytes. PURPOSE: This phase I/II trial is studying the side effects and best dose of everolim...
What is the current status of trial NCT00935792?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2009-07. Estimated completion is 2015-12.
What conditions does trial NCT00935792 study?
This clinical trial studies the following conditions: Lymphocytic Leukemia.
What interventions are being tested in trial NCT00935792?
The interventions under investigation include: everolimus (DRUG), alemtuzumab (DRUG).
Who is sponsoring clinical trial NCT00935792?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00935792 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
RECRUITING · Phase 1
-
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
COMPLETED · Phase 1
-
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
COMPLETED · Early Phase 1
-
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
COMPLETED · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.